Tags : IMPACT study


GSK’s Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol ‘FF/UMEC/VI’) Receives Expanded Level Approval

Shots: The IMPACT study involves assessing of Trelegy Ellipta (qd,100/62.5/25mcg) vs (ICS/LABA Relvar/Breo Ellipta (FF/VI)) (100/25mcg) & ((LAMA)/LABA Anoro Ellipta (UMEC/VI)) (62.5/25mcg) in patients with COPD The Expanded label approval will serve as a maintenance treatment for patients with moderate-to-severe COPD and shown effective results in comparison to ICS, LABA & LAMA. In 2017, Trelegy […]Read More